{"DataElement":{"publicId":"5143352","version":"1","preferredName":"Primary Immunodeficiency Prior Therapy Type","preferredDefinition":"Name to represent an therapy modality or approach used to treat a patient with Primary immunodeficiencies (PIs) at a point in time before an evaluation or treatment time point.","longName":"PRIM_IMMUD_PR_TX_TP","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"5142733","version":"1","preferredName":"Prior Therapy Primary Immunodeficiency Description","preferredDefinition":"Primary immunodeficiencies (PIs) are a heterogeneous group of disorders, which affect cellular and humoral immunity or non-specific host defense mechanisms mediated by complement proteins, and cells such as phagocytes and natural killer (NK) cells. These disorders of the immune system cause increased susceptibility to infection, autoimmune disease, and malignancy. Most of PIs are due to genetic defects that affect cell maturation or function at different levels during hematopoiesis. Disruption of the cellular immunity is observed in patients with defects in T cells or both T and B cells. These cellular immunodeficiencies comprise 20% of all PIs. Disorders of humoral immunity affect B-cell differentiation and antibody production. They account for 70% of all PIs._Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process._A written or verbal account, representation, statement, or explanation of something.","longName":"5142731v1.0:2222846v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"5142731","version":"1","preferredName":"Prior Therapy Primary Immunodeficiency Pathway","preferredDefinition":"An indicator that a person has been previously treated for the same condition or with the same therapy.:Primary immunodeficiencies (PIs) are a heterogeneous group of disorders, which affect cellular and humoral immunity or non-specific host defense mechanisms mediated by complement proteins, and cells such as phagocytes and natural killer (NK) cells. These disorders of the immune system cause increased susceptibility to infection, autoimmune disease, and malignancy. Most of PIs are due to genetic defects that affect cell maturation or function at different levels during hematopoiesis. Disruption of the cellular immunity is observed in patients with defects in T cells or both T and B cells. These cellular immunodeficiencies comprise 20% of all PIs. Disorders of humoral immunity affect B-cell differentiation and antibody production. They account for 70% of all PIs.","longName":"C16124:C91500","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior Therapy","conceptCode":"C16124","definition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Primary Immunodeficiency Pathway","conceptCode":"C91500","definition":"Primary immunodeficiencies (PIs) are a heterogeneous group of disorders, which affect cellular and humoral immunity or non-specific host defense mechanisms mediated by complement proteins, and cells such as phagocytes and natural killer (NK) cells. These disorders of the immune system cause increased susceptibility to infection, autoimmune disease, and malignancy. Most of PIs are due to genetic defects that affect cell maturation or function at different levels during hematopoiesis. Disruption of the cellular immunity is observed in patients with defects in T cells or both T and B cells. These cellular immunodeficiencies comprise 20% of all PIs. Disorders of humoral immunity affect B-cell differentiation and antibody production. They account for 70% of all PIs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CAF271E-5270-E13D-E050-BB89AD432669","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2222846","version":"1","preferredName":"Description","preferredDefinition":"A statement or an account describing something.","longName":"C25365","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Description","conceptCode":"C25365","definition":"A written or verbal account, representation, statement, or explanation of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6211337-E099-4E34-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER_EVS","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CAF271E-527E-E13D-E050-BB89AD432669","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"03/06/2013 - tc - Removed retired concept C15368 and replaced with NCIt concept C49236.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5142771","version":"1","preferredName":"Prior Therapy Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"PRIOR_TX_TP","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Bone Marrow Transplant","valueDescription":"Bone Marrow Transplantation","ValueMeaning":{"publicId":"3021570","version":"1","preferredName":"Bone Marrow Transplantation","longName":"3021570","preferredDefinition":"A procedure to replace diseased or pathologic bone marrow with transplanted healthy bone marrow cells. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Marrow Transplantation","conceptCode":"C15194","definition":"A procedure to replace diseased bone marrow with transplanted healthy bone marrow cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"818DED3A-49AA-17D3-E040-BB89AD4304FC","latestVersionIndicator":"Yes","beginDate":"2010-03-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-11","modifiedBy":"TAYLORT","dateModified":"2020-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CAF3096-97D0-003C-E050-BB89AD4320A2","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Radiation (NOS)","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2567129","version":"1","preferredName":"Radiation Therapy","longName":"2567129","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D346-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-21","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-10-21","modifiedBy":"KUMMEROA","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CAF3096-97E4-003C-E050-BB89AD4320A2","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Chemotherapy (NOS)","valueDescription":"Chemotherapy","ValueMeaning":{"publicId":"5102333","version":"1","preferredName":"Chemotherapy","longName":"5102333","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-0232-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CAF3096-97F8-003C-E050-BB89AD4320A2","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Chemotherapy multiple agents systemic","valueDescription":"Chemotherapy multiple agents systemic","ValueMeaning":{"publicId":"5142772","version":"1","preferredName":"Chemotherapy multiple agents systemic","longName":"5142772","preferredDefinition":"Systemic chemotherapy with a multiple agent regimen. All routes of administration are acceptable as long as the regimen is intended for systemic therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Agent Systemic Chemotherapy","conceptCode":"C118618","definition":"Systemic chemotherapy with a multiple agent regimen. All routes of administration are acceptable as long as the regimen is intended for systemic therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CAF3096-9802-003C-E050-BB89AD4320A2","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CAF3096-981B-003C-E050-BB89AD4320A2","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Chemotherapy single agent systemic","valueDescription":"Single Agent Systemic Chemotherapy","ValueMeaning":{"publicId":"5142773","version":"1","preferredName":"Single Agent Systemic Chemotherapy","longName":"5142773","preferredDefinition":"Systemic chemotherapy with a single agent regimen. All routes of administration are acceptable as long as the agent is intended for systemic therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Single Agent Systemic Chemotherapy","conceptCode":"C15756","definition":"Systemic chemotherapy with a single agent regimen. All routes of administration are acceptable as long as the agent is intended for systemic therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CAF3096-9825-003C-E050-BB89AD4320A2","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CAF3096-983D-003C-E050-BB89AD4320A2","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Surgery","valueDescription":"Surgical procedure","ValueMeaning":{"publicId":"2567130","version":"1","preferredName":"Surgical procedure","longName":"2567130","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Surgical Procedure","conceptCode":"C15329","definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D347-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-21","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-10-21","modifiedBy":"REEVESD","dateModified":"2012-07-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CAF3096-9848-003C-E050-BB89AD4320A2","beginDate":"2003-10-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Targeted therapy: small molecule","valueDescription":"Small Molecule Targeted Therapy","ValueMeaning":{"publicId":"5143294","version":"1","preferredName":"Small Molecule Targeted Therapy","longName":"5143294","preferredDefinition":"A molecule with a low molecular weight that is not determined by a genome sequence.: A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Molecule","conceptCode":"C48809","definition":"A molecule with a low molecular weight that is not determined by a genome sequence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Targeted Therapy","conceptCode":"C93352","definition":"A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CB1C481-C54A-1475-E050-BB89AD433B19","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CB1C481-C563-1475-E050-BB89AD433B19","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Immunosuppression","valueDescription":"Immunosuppressive Therapy","ValueMeaning":{"publicId":"2935384","version":"1","preferredName":"Immunosuppressive Therapy","longName":"2935384","preferredDefinition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunosuppressive Therapy","conceptCode":"C15261","definition":"deliberate suppression of immune system function for experimental or therapeutic purposes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71E8ECC4-27E1-1CB5-E040-BB89AD431000","latestVersionIndicator":"Yes","beginDate":"2009-08-24","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-08-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CB1C481-C577-1475-E050-BB89AD433B19","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Immunoglobulin","valueDescription":"Immunoglobulin","ValueMeaning":{"publicId":"5143295","version":"1","preferredName":"Immunoglobulin","longName":"5143295","preferredDefinition":"Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunoglobulin","conceptCode":"C572","definition":"Any of the structurally related glycoproteins that function as antibodies. They are divided into five classes (IGA, IGD, IGE, IGG, IGM) on the basis of structure and biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CB1C481-C581-1475-E050-BB89AD433B19","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CB1C481-C59A-1475-E050-BB89AD433B19","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Intrathecal Chemotherapy","valueDescription":"Intrathecal Chemotherapy","ValueMeaning":{"publicId":"5143296","version":"1","preferredName":"Intrathecal Chemotherapy","longName":"5143296","preferredDefinition":"Treatment in which anticancer drugs are injected into the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Chemotherapy","conceptCode":"C15750","definition":"Chemotherapy delivered via the spinal canal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CB1C481-C5A4-1475-E050-BB89AD433B19","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CB1C481-C5BC-1475-E050-BB89AD433B19","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Gene Transfer","valueDescription":"Gene Transfer","ValueMeaning":{"publicId":"2571541","version":"1","preferredName":"Gene Transfer","longName":"2571541","preferredDefinition":"Incorporation of new DNA into an organism's cells, usually by a vector such as a modified virus. Used in gene therapy.(From Human Genome Project Information).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gene Transfer","conceptCode":"C20185","definition":"Incorporation of new DNA into an organism's cells, usually by a vector such as a modified virus. Used in gene therapy.(From Human Genome Project Information).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E482-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-08-13","modifiedBy":"REEVESD","dateModified":"2006-03-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CB1C481-C5C7-1475-E050-BB89AD433B19","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Targeted therapy: monoclonal antibody","valueDescription":"Monoclonal Antibody Targeted Therapy","ValueMeaning":{"publicId":"5143351","version":"1","preferredName":"Monoclonal Antibody Targeted Therapy","longName":"5143351","preferredDefinition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.: A type of treatment that uses drugs or other substances, such as monoclonal antibodies, to identify and attack specific cancer cells. Targeted therapy may have fewer side effects than other types of cancer treatments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Targeted Therapy","conceptCode":"C93352","definition":"A type of cancer treatment that uses testing and medication to more precisely identify and treat cancer. These treatments target and disable genes or proteins necessary to the proliferation of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CB1C481-C601-1475-E050-BB89AD433B19","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2CB1C481-C61A-1475-E050-BB89AD433B19","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"ONEDATA","dateModified":"2016-02-26","deletedIndicator":"No"},{"value":"Antibiotic","valueDescription":"Antibiotic","ValueMeaning":{"publicId":"2574589","version":"1","preferredName":"Antibiotic","longName":"2574589","preferredDefinition":"(an-tih-by-AH-tik) A drug used to treat infections caused by bacteria and other microorganisms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antibiotic","conceptCode":"C258","definition":"Substances naturally produced by microorganisms or their derivatives that selectively target microorganisms not humans. Antibiotics kill or inhibit the growth of microorganisms by targeting components of the microbial cell absent from human cells, including bacterial cell walls, cell membrane, and 30S or 50S ribosomal subunits. These substances are used in the treatment of bacterial and other microbial infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F06A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-26","modifiedBy":"ONEDATA","dateModified":"2005-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3426CE46-6214-4CFE-E050-BB89AD43712E","beginDate":"2016-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-31","modifiedBy":"ONEDATA","dateModified":"2016-05-31","deletedIndicator":"No"},{"value":"Interferon","valueDescription":"Interferon","ValueMeaning":{"publicId":"2567432","version":"1","preferredName":"Interferon","longName":"2567432","preferredDefinition":"RAEB: Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. (MSH98)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interferon","conceptCode":"C20493","definition":"Human interferons have been classified into 3 groups: alpha, beta, and gamma. Both alpha- and beta-IFNs, previously designated type I, are acid-stable, but they differ immunologically and in regard to some biologic and physiochemical properties. The IFNs produced by virus-stimulated leukocytes (leukocyte IFNs) are predominantly of the alpha type. Those produced by lymphoblastoid cells are about 90% alpha and 10% beta. Induced fibroblasts produce mainly or exclusively the beta type. The alpha- and beta-IFNs differ widely in amino acid sequence. The gamma or immune IFNs, which are produced by T lymphocytes in response to mitogens or to antigens to which they are sensitized, are acid-labile and serologically distinct from alpha- and beta-IFNs. (from OMIM 147570)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D475-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3426CE46-621E-4CFE-E050-BB89AD43712E","beginDate":"2016-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-31","modifiedBy":"ONEDATA","dateModified":"2016-05-31","deletedIndicator":"No"},{"value":"Supplement","valueDescription":"Dietary Supplement","ValueMeaning":{"publicId":"5284015","version":"1","preferredName":"Dietary Supplement","longName":"5284015","preferredDefinition":"Oral preparations containing dietary ingredient(s) intended to supplement the diet.  Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dietary Supplement","conceptCode":"C1505","definition":"Oral preparations containing dietary ingredient(s) intended to supplement the diet.  Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3426CE46-6228-4CFE-E050-BB89AD43712E","latestVersionIndicator":"Yes","beginDate":"2016-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3426CE46-6241-4CFE-E050-BB89AD43712E","beginDate":"2016-05-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-31","modifiedBy":"ONEDATA","dateModified":"2016-05-31","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ADEERS:NCI/CTEP Adverse Event Expedited Report System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2CAF3096-97B1-003C-E050-BB89AD4320A2","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"REEVESD","dateModified":"2016-10-21","changeDescription":"Curated to support NCI CCR Primary Immunodeficiency CRF Template.  Value sets are prescribed for that specific set of requirements.10.21.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Primary Immunodeficiency Prio","type":"Preferred Question Text","description":"Primary Immunodeficiency Prior Therapy","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"2CB2C7B9-1ADC-1DFE-E050-BB89AD433C1E","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"REEVESD","dateModified":"2016-04-05","changeDescription":"Curated to support NCI CCR primary immunodeficiency trial.4.5.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}